
Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.

May 12, 2022
Synthetic control arm (SCA) methods are statistical methods that are seeing rapidly increasing use in comparative...
Read article

April 22, 2022
Cytel’s Single Arm Trials Panel Selected as a Part of ISPOR 2022
This past decade has undoubtedly witnessed an increase in the number of single arm trials submitted to HTA bodies....
Read article

January 20, 2022
Is Borrowing Outcomes from US or China the Future for Rare Conditions?
Limited patient populations resulting in small study sample sizes is a difficulty associated with the development of...
Read article

November 23, 2021
Using Single Arm Trials for HTA Submissions: Dr. Heeg and Maria Rizzo
A randomized clinical trial (RCT) is the gold standard approach to demonstrate the efficacy and safety of novel...
Read article

November 11, 2021
Championing RWE & HEOR at Virtual ISPOR Europe 2021
The value of Real World Evidence (RWE) is well known to many stakeholders, but its full potential for market access and...
Read article

November 4, 2021
Join Cytel for HEOR Insights at ISPOR Europe 2021
The prominent European conference for Health Economics and Outcomes Research (HEOR), ISPOR Europe 2021, is around the...
Read article

May 20, 2021
Quantitative Bias Analysis to Strengthen Comparative Effectiveness
As more payers and HTA agencies turn to real world data to compare the effectiveness of various treatment effects, two...
Read article

May 13, 2021
An Interview with Radek Wasiak, Head of Real World and Advanced Analytics at Cytel
Cytel’s HEOR and RWE Expertise has grown quite significantly in the past year. Could you speak a little bit about the...
Read article

May 5, 2021
Meet our Global HEOR and RWE Experts: Virtual ISPOR 2021
Cytel’s team of HEOR and Real-World Evidence (RWE) experts are all set to make a splash at the Virtual ISPOR on May 17...
Read article